GAITHERSBURG, Md., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced today that representatives of Novavax, along with a number of its research collaborators, will be making multiple oral presentations and poster presentations related to Novavax' RSV F-protein nanoparticle vaccine candidate (RSV F Vaccine) at the 9th International Respiratory Syncytial Virus Symposium to be held November 9 – 13, 2014 in Stellenbosch, South Africa.
Poster, presentation titles, and presenters are listed below:
- "Maternal Immunization of Pregnant Baboons with the RSV F Nanoparticle Vaccine Leads to Transplacental Transfer of High Affinity Functional Antibodies in Infants."
Robert C. Welliver, M.D., Professor of Pediatrics and Section Chief, The University of Oklahoma Health Sciences Center
- "Placental Transfer of Anti-RSV F Maternal Antibody in Rabbits and Guinea Pigs Immunized with an RSV F Nanoparticle Vaccine Co-administered with Aluminum Phosphate."
Hanxin Lu, Ph.D., Senior Scientist, Novavax, Inc.
- "A Phase II Randomized, Observer-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Immunogenicity and Safety of Multiple Formulations of an RSV F Nanoparticle Vaccine with Aluminum, in Healthy Women of Child-bearing Age."
Nigel Thomas, Ph.D., Vice President, Clinical Operations, Novavax, Inc.
- "Immunogenicity of the RSV F Nanoparticle Vaccine and Induction of Palivizumab Competing Antibodies: Review of Immunogenicity Data and Consideration of the Clinical Relevance."
Gregory Glenn, M.D., Senior Vice President, Research and Development, Novavax, Inc.
- "Cotton Rats Vaccinated with RSV F-Protein Nanoparticle Vaccine are Protected from Infection with RSV Wild Type and Palivizumab Escape Mutant Virus."
Pedro Piedra, M.D., Professor of Molecular Virology and Microbiology, Baylor College of Medicine
RSV is a widespread disease that causes infections of the lower respiratory tract. While RSV affects individuals of all ages, it acutely impacts infants, the elderly, young children and others with compromised immune systems. RSV is the number one cause of hospitalization in infants ages 0 to 12 months in the U.S. and is a significant cause of infant morbidity and mortality globally. Current estimates indicate that RSV is responsible for over 30 million new acute lower respiratory infection episodes and between 150,000 and 200,000 deaths in children under five years old. In the U.S., nearly all children become infected with RSV before they are two years old; it has been associated with 20% of hospitalizations and 15% of office visits for acute respiratory infection in young children. The World Health Organization (WHO) estimates that the global disease burden for RSV is 64 million cases. Because there is no approved prophylactic vaccine, an RSV vaccine has the potential to protect millions of patients from this far-reaching unmet medical need.
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating novel vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using innovative proprietary recombinant nanoparticle vaccine technology, the company produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases. Additional information about Novavax is available on the company's website, novavax.com.
CONTACT: Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Novavax, Inc. 240-268-2000 David Schull or Andrea Flynn, Ph.D. Russo Partners, LLC 212-845-4271 David.firstname.lastname@example.org Andrea.email@example.com